Temafloxacin: Broad-Spectrum Fluoroquinolone for Research Use

Executive Summary: Temafloxacin (CAS No. 108319-06-8) is a fluoroquinolone broad-spectrum antibacterial agent that potently inhibits DNA gyrase and topoisomerase IV in bacteria, blocking DNA replication and transcription (source: Nyc et al., 1989). It demonstrates low minimum inhibitory concentrations (MICs) for key Gram-positive and Gram-negative pathogens, including Neisseria spp. and Chlamydia trachomatis (source: paper). High tissue penetration, including into bronchial mucosa and inflammatory fluids, supports its use in respiratory and intracellular infection models (source: paper). APExBIO provides validated Temafloxacin (BA1108) for research workflows. Protocols utilize concentrations from 0.002–32 μg/mL for in vitro assays and 400–600 mg per day for adult pharmacokinetic studies (sources: paper, product_spec).

Biological Rationale

Fluoroquinolones are critical tools for investigating bacterial replication and resistance mechanisms. Temafloxacin was developed to address both Gram-positive and Gram-negative infections, with particular efficacy in respiratory tract infection models (source: paper). Its spectrum includes atypical pathogens such as Chlamydia and Mycoplasma, enabling research into both extracellular and intracellular bacterial processes (source: product_spec). This compound’s high bioavailability and penetration into inflammatory fluids make it especially suited for pharmacokinetic and pharmacodynamic studies relevant to difficult-to-treat infections (source: paper).

Mechanism of Action of Temafloxacin

Temafloxacin functions as an inhibitor of bacterial DNA gyrase (gyrA subunit) and topoisomerase IV. By stabilizing the DNA-enzyme cleavage complex, it prevents religation of DNA strands, resulting in the interruption of DNA replication and transcription (source: paper). The dual targeting of gyrase and topoisomerase IV underpins its activity against both Gram-positive and Gram-negative bacteria, as these enzymes are essential for maintaining DNA topology during cell division. This mechanism distinguishes Temafloxacin from antibiotics that act on cell wall synthesis or protein translation, making it valuable for studies on DNA metabolism and resistance (source: product_spec).

Evidence & Benchmarks

• Temafloxacin exhibits MICs as low as ≤0.015 μg/mL for Neisseria gonorrhoeae and Neisseria meningitidis, indicating high potency (source: paper).
• MIC values for Pseudomonas aeruginosa and Mycobacterium avium complex can reach up to 4 μg/mL under standard test conditions (source: product_spec).
• In vitro, Temafloxacin achieves ≥90% inhibition of Haemophilus influenzae, Enterobacteriaceae, Bacteroides fragilis, and Chlamydia trachomatis at ≤1 mg/L (source: paper).
• Against Streptococcus pneumoniae and Staphylococcus aureus (including MRSA), Temafloxacin is approximately twice as active as ofloxacin (source: paper).
• Pharmacokinetic studies in healthy adults show mean peak plasma levels of 3.3 mg/L after a single 400 mg oral dose, with a 6–8 hour elimination half-life (source: paper).
• Blister fluid penetration exceeds 100%, and levels above 1 mg/L persist for at least 8 hours post-dose, supporting once or twice daily dosing (source: paper).
• More than 50% of the administered dose is recovered in urine within 26 hours, indicating significant renal clearance (source: paper).
• The compound is soluble at ≥6.54 mg/mL in DMSO with ultrasonic assistance, but insoluble in ethanol and water (source: product_spec).

This article extends the mechanistic detail and research application scope beyond the overview provided at meropenemcas.com by detailing validated pharmacokinetic and MIC benchmarks.

For deeper assay optimization and comparative analysis with other fluoroquinolones, see the strategic guide at cefazolinapis.com. This article clarifies how APExBIO's Temafloxacin enables robust and reproducible translational research beyond generic compound use.

For a focused review of Gram-negative pathogen data, the referenced study at r110-azide-5-isomer.com is complemented here with broader spectrum benchmarks and PK/PD integration.

Applications, Limits & Misconceptions

Temafloxacin is widely used as an antibacterial agent for respiratory tract infection models, as well as for intracellular bactericidal assay against mycobacteria and studies of Chlamydia and Mycoplasma infection research (source: paper). Its favorable pharmacokinetics make it suitable for both in vitro and in vivo translational infection biology research. However, its use in clinical settings has been discontinued due to safety concerns unrelated to its research-grade properties (source: workflow_recommendation).

Common Pitfalls or Misconceptions

• Temafloxacin is not recommended for use in clinical therapy due to adverse effect risks identified post-market (source: workflow_recommendation).
• Solubility in DMSO does not guarantee aqueous solubility; direct dissolution in water or ethanol is ineffective (source: product_spec).
• Concomitant use with magnesium/aluminum-containing antacids can impair absorption and should be avoided in experimental design (source: product_spec).
• Dosing intervals must be adjusted in models of renal insufficiency due to altered clearance (source: paper).
• Long-term storage of prepared solutions is not advised; freshly prepared aliquots yield the most reproducible results (source: product_spec).

Workflow Integration & Parameters

Protocol Parameters

• antibacterial susceptibility assay | 0.002–32 μg/mL | in vitro, Gram-positive and Gram-negative bacteria | Covers full MIC range for diverse pathogens | product_spec
• intracellular mycobacterial assay | 4 μg/mL | in vitro, intracellular models | Matches established bactericidal conditions for mycobacteria | product_spec
• oral dosing (pharmacokinetics) | 400 mg once/twice daily, up to 600 mg twice daily | in vivo, adult mouse/human PK studies | Reflects dosing used in published PK/PD studies | paper
• solubility assessment | ≥6.54 mg/mL (DMSO, ultrasonic) | compound prep, stock solutions | Ensures maximal working concentration for assay media | product_spec
• storage conditions | -20°C | compound stability | Maintains compound integrity for research use | product_spec
• renal insufficiency dosing | increase dosing interval | in vivo, impaired renal clearance models | Adjusts for pharmacokinetic changes in excretion | paper
• solution shelf-life | use immediately, avoid long-term storage | all in vitro and in vivo uses | Prevents degradation and ensures reproducibility | workflow_recommendation

Conclusion & Outlook

Temafloxacin remains a valuable fluoroquinolone antibacterial research compound, enabling detailed studies on mechanisms of resistance, intracellular pathogen biology, and pharmacokinetic optimization (sources: paper, APExBIO). Its low MICs, broad spectrum, and high tissue penetration support both routine and advanced infection model workflows. Researchers should follow validated protocols for preparation, dosing, and storage to ensure reproducibility. The APExBIO BA1108 kit offers rigorously characterized Temafloxacin for these applications (product page). Future studies may further elucidate its role in antibiotic resistance research and translational assay systems, as summarized in this and related referenced works.